Rate of decline in FEV 1: Is emphysema the culprit?

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 1, 2012, Pages 2-3

  Washko, George R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOBACCO SMOKE; BRONCHODILATING AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; EDITORIAL; EMPHYSEMA; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG FUNCTION; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; SPIROMETRY; DRUG EFFECT; FEMALE; MALE; NOTE; PATHOPHYSIOLOGY; RADIOGRAPHY; RESPIRATORY FUNCTION;

BRONCHODILATOR AGENTS; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY PHYSIOLOGICAL PHENOMENA;

EID: 84855265595     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201111-1938ED     Document Type: Editorial

References (14)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-1648. (Pubitemid 8124466)
2. Lee PN, Fry JS. Systematic review of the evidence relating FEV1 decline to giving up smoking. BMC Med 2010;8:84.
3. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, et al.; Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:44-52.
4. Mohamed Hoesein FA, de Hoop B, Zanen P, Gietema H, Kruitwagen CL, van Ginneken B, Isgum I, Mol C, van Klaveren RJ, Dijkstra AE, et al. CT-quantified emphysema in male heavy smokers: association with lung function decline. Thorax 2011;66:782-787.
5. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-1192.
6. Houghton AM, Quintero PA, Perkins DL, Kobayashi DK, Kelley DG, Marconcini LA, Mecham RP, Senior RM, Shapiro SD. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 2006;116:753-759. (Pubitemid 43326884)
7. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269-280. (Pubitemid 30490396)
8. Owen CA. Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2: 373-385; discussion 394-375.
9. Shapiro SD. Vascular atrophy and VEGFR-2 signaling: old theories of pulmonary emphysema meet new data. J Clin Invest 2000;106:1309-1310.
10. Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. J Clin Invest 2008;118:394-402. (Pubitemid 351206526)
11. Suki B, Lutchen KR, Ingenito EP. On the progressive nature of emphysema: roles of proteases, inflammation, and mechanical forces. Am J Respir Crit Care Med 2003;168:516-521. (Pubitemid 37088592)
12. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, Criner GJ, Kim V, Bowler RP, Hanania NA, et al. Chronic obstructive pulmonary disease exacerbations in the COPDgene study: associated radiologic phenotypes. Radiology 2011;261:274-282.
13. Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJ, Austin JH, Jiang R, Lovasi GS, Barr RG. Cigarette smoking is associated with subclinical parenchymal lung disease: the multiethnic study of atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med 2009;180:407-414.
14. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, Estepar RS, Lynch DA, Brehm JM, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011;364:897-906.